Insulin sensitivity and related cytokines, chemokines, and adipokines in polymyalgia rheumatica

Scandinavian Journal of Rheumatology

Volumn 39, Issue 5, 2010, Pages 402-408

  Kreiner, F ^a   Galbo, H ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; GLUCOSE; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; CCL2 PROTEIN, HUMAN; GLUCOCORTICOID; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATIC POLYMYALGIA; TREATMENT OUTCOME; BLOOD; CASE CONTROL STUDY; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PHYSIOLOGY; POLYMYALGIA RHEUMATICA; VERY ELDERLY;

ADIPONECTIN; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINES; CYTOKINES; FEMALE; GLUCOCORTICOIDS; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; INTERLEUKIN-8; LEPTIN; MALE; MIDDLE AGED; MOTOR ACTIVITY; POLYMYALGIA RHEUMATICA; PREDNISOLONE; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957949228     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009741003631479     Document Type: Article

References (52)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheu-matica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
2. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-8.
3. Mikines KJ, Richter EA, Dela F, Galbo H. Seven days of bed rest decrease insulin action on glucose uptake in leg and whole body. J Appl Physiol 1991;70:1245-54.
4. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7.
5. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004;31:867-74.
6. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8.
7. Sivalingam SP, Thumboo J, Vasoo S, Thio ST, Tse C, Fong KY. In vivo pro-and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann Acad Med Singapore 2007;36:96-9.
8. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponec-tin, leptin, resistin and visfatin in patients with rheumatoid arthri-tis. Ann Rheum Dis 2006;65:1198-201.
9. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006;54:2765-75.
10. Tappy L, Randin D, Vollenweider P, Vollenweider L, Paquot N, Scherrer U, et al. Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab 1994;79:1063-9.
11. Giorgino F, Almahfouz A, Goodyear LJ, Smith RJ. Glucocorti-coid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 1993;91:2020-30.
12. Svenson KL, Pollare T, Lithell H, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988;37:125-30.
13. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008;58:2105-12.
14. Pemberton PW, Ahmad Y, Bodill H, Lokko D, Hider SL, Yates AP, et al. Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis. BMC Res Notes 2009;2:83.
15. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglyc-emic insulin clamp. Diabetes Care 1999;22:1462-70.
17. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121:S21-31.
18. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997;100:2094-8.
19. Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with meta-bolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 2008;14:74-7.
20. Korczowska I, Olewicz-Gawlik A, Trefler J, Hrycaj P, Krzysztof Lacki J. Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients? Clin Rheumatol 2008;27:565-72.
21. Mikines KJ, Sonne B, Farrell PA, Tronier B, Galbo H. Effect of training on the dose-response relationship for insulin action in men. J Appl Physiol 1989;66:695-703.
22. Mikines KJ, Sonne B, Farrell PA, Tronier B, Galbo H. Effect of physical exercise on sensitivity and responsiveness to insulin in humans. Am J Physiol 1988;254:E248-59.
23. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
24. Uddhammar A, Sundqvist KG, Ellis B, Rantapaa-Dahlqvist S. Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol 1998;37:766-9.
25. Sulli A, Montecucco CM, Caporali R, Cavagna L, Montagna P, Capellino S, et al. Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:307-14.
26. Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006;65:1438-43.
27. Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003;30:760-3.
28. Migliore A, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to dia-betes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci 2005;9:373-8.
29. Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631-9.
30. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
31. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-8.
32. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-84.
33. Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treat-ment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg 2007;62:218-22.
34. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Regula-tion of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:529-33.
35. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
36. Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B. Associa-tion between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 2003;148:535-42.
37. Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol 2007;18:258-62.
38. Pulsatelli L, Meliconi R, Boiardi L, Macchioni P, Salvarani C, Facchini A. Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. Clin Exp Rheumatol 1998;16:263-8.
39. Ellingsen T, Elling P, Olson A, Elling H, Baandrup U, Matsushima K, et al. Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica. Ann Rheum Dis 2000;59:775-80.
40. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285:E1072-80.
41. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
42. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003;9:RA55-61.
43. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442-50.
44. Jang C, Inder WJ, Obeyesekere VR, Alford FP. Adiponectin, skeletal muscle adiponectin receptor expression and insulin resistance following dexamethasone. Clin Endocrinol (Oxf) 2008;69:745-50.
45. Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. J Immunol 2006;176:4468-78.
46. Fantuzzi G. Adiponectin and inflammation: consensus and contro-versy. J Allergy Clin Immunol 2008;121:326-30.
47. Nagashima T, Okubo-Fornbacher H, Aoki Y, Kamata Y, Kimura H, Kamimura T, et al. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J Rheumatol 2008;35:936-8.
48. Harle P, Sarzi-Puttini P, Cutolo M, Straub RH. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheu-matoid arthritis. Ann Rheum Dis 2006;65:970-1.
49. Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005;64:1195-8.
50. Bruder ED, Jacobson L, Raff H. Plasma leptin and ghrelin in the neonatal rat: interaction of dexamethasone and hypoxia. J Endo-crinol 2005;185:477-84.
51. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997;272:10585-93.
52. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.